Brookfield Corp’s Sarepta Therapeutics SRPT Stock Holding History

Brookfield Corp’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-8,344	Closed	-$956K	–	473
2023 Q2	$956K	Buy	+8,344	New	+$1.08M	﹤0.01%	468

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Brookfield Corp's SRPT Position: Q3 2023 in Review

Brookfield Corp sold out of Sarepta Therapeutics (SRPT) in Q3 2023, closing a stake of 8,344 shares — an estimated $956K sold.

Brookfield Corp first reported a position in SRPT in Q2 2023 and held it in 1 quarter. The position peaked at $956K in Q2 2023. 395 funds tracked by Wall St. Rank hold SRPT as of Q3 2023.

Brookfield Corp reported no remaining Sarepta Therapeutics position as of Q3 2023 after selling out during the quarter.
Brookfield Corp sold 8,344 Sarepta Therapeutics shares in Q3 2023, an estimated $956K.
Brookfield Corp first reported a position in Sarepta Therapeutics in Q2 2023 and held it in 1 quarter.
Brookfield Corp's Sarepta Therapeutics position peaked at $956K in Q2 2023.
395 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2023.

Based on Brookfield Corp's 13F filing for Q3 2023, filed 14 Nov 2023.